Boehringer Ingelheim has signed a preclinical program contract with a British biotech worth $500 million in a deal that is anticipated to provide a new oral form of treatment to a range of autoimmune and inflammatory diseases.
The Oxford, England-based biotech may also be entitled to upfront and milestone payments exceeding $500 million in exchange for the global exclusive license to the small molecule inhibitor program of Sitryx, but the companies did not provide a breakdown of the financials. Moreover, Sitryx will be given a percentage of the royalties in case a drug gets to the market.
Boehringer is pegging its hopes on the program providing a new oral approach and accuracy of modulating disease-driving immune cells, the pharma described in a release belonging to the 26th of February.
In 2018, Sitryx, an autoimmune-based company that is present in Boston, was founded through the support of GSK and SV Health Investors. Sitryx had been looking at the contribution of metabolic pathways to the work of immune cells since then, with Eli Lilly paying the biotech up to four autoimmune drugs in 2020.
One of such drugs, an itaconate mimetic named SYX-1042, was then subjected to a phase 1 trial by the pharma before it repurchased the asset in August 2025 due to strategic reasons and reprioritization of Lilly’s pain and inflammation portfolio.
The returned SYX-1042 now becomes the most advanced Sitryx drug with SYX-5219 (PKM2 modulator) that is in phase 1 development to treat atopic dermatitis. The biotech has GLS1 and SIK2 inhibitors in its preclinical pipeline, which are used for allergic asthma and ulcerative colitis, respectively.
The current deal with Boehring, Sitryx CEO Iain Kilty, announced today, is a significant milestone for our company and a clear confirmation of the power of our pipeline and our ability to translate immunometabolic targets into meaningful therapeutic candidates.
Kilty stated that the preclinical program is out-licensed to Boehringer Ingelheim and that its capabilities in the US are global in immunology and drug development, and this will enable this program to provide significant benefits to patients around the world.
The agreement with Sityrx is an extension of a hectic few months of dealmaking in Boehringer. Already this year, the German drugmaker has signed a 1.05 billion-euro ($1.26 billion) biobucks deal with Simcere preclinical inflammatory bowel disease bispecific antibody and a $120 million kidney-based agreement with Variant Bio.
In the meantime, the pharma has currently had a clinical-stage immunology pipeline with such drugs as the sGC activator avenciguat in systemic sclerosis and a TREM-1 antagonist in ulcerative colitis. Carine Boustany, head of research, immunology and respiratory diseases at Boehringer, added that autoimmune and inflammatory diseases were on the list of areas that needed rapid innovation.
Boehringer Expands Oral Autoimmune Strategy
Boehringer Ingelheim has entered a landmark agreement valued at up to $500 million with a British biotech company to advance oral treatments for autoimmune illnesses. The deal highlights Boehringer’s long-term commitment to next-generation immunology therapies that improve patient convenience and outcomes.
Focus on Oral Autoimmune Therapies
Unlike injectable biologics, the oral therapies targeted in this collaboration aim to simplify treatment for chronic autoimmune conditions. Boehringer is leveraging the British biotech’s proprietary platform to develop small-molecule drugs designed to modulate immune pathways while offering easier administration.
Strategic Value for Boehringer
The agreement includes upfront payments, research funding, and milestone-based compensation that could total $500 million. For Boehringer, the deal strengthens its autoimmune pipeline and supports its broader strategy to diversify beyond traditional biologics into orally delivered medicines.
Impact on the Autoimmune Drug Market
Autoimmune diseases such as rheumatoid arthritis, lupus, and inflammatory bowel disease remain areas of high unmet need. By focusing on oral therapies, Boehringer aims to address long-standing challenges around adherence, manufacturing complexity, and healthcare costs.
Looking Ahead
With this partnership, Boehringer positions itself as a key player in the next wave of autoimmune innovation. Clinical development milestones expected over the coming years will determine how quickly these oral treatments move toward late-stage trials and potential regulatory approvals.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
